Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 7/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15466961 | 1.00 | PDE2A (0.36) | PDE2AKCNN4KDRGRM2HCRTR1 | |
| SCHEMBL15467957 | 0.90 | PDE2A (0.38) | PDE2AKCNN4GRM2TRPV1P2RX7 | |
| SCHEMBL15467955 | 0.90 | PDE2A (0.38) | PDE2AKCNN4GRM2TRPV1P2RX7 | |
| SCHEMBL15467900 | 0.89 | PDE2A (0.37) | PDE2AKCNN4GRM2TRPV1P2RX7 | |
| SCHEMBL15467902 | 0.89 | PDE2A (0.37) | PDE2AKCNN4GRM2TRPV1P2RX7 | |
| SCHEMBL15467424 | 0.87 | PDE2A (0.35) | PDE2AKCNN4KDRGRM2P2RX7 | |
| SCHEMBL15467425 | 0.87 | PDE2A (0.35) | PDE2AKCNN4KDRGRM2P2RX7 | |
| SCHEMBL15469495 | 0.86 | BACE1 (0.32) | KDRRET | |
| Hydrochloric Acid SCHEMBL15567921 | 0.82 | P2RX7 (0.38) | PDE2AKCNN4GRM2TRPV1P2RX7 | |
| Hydrochloric Acid SCHEMBL15567923 | 0.82 | P2RX7 (0.38) | PDE2AKCNN4GRM2TRPV1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | PDE2A 891/4885KCNN4 78/4885KDR 4242/4885 |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | PDE2A 891/4885KCNN4 78/4885KDR 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.